Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
AYTU vs PRGO vs TEVA vs MCK vs CAH
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Medical - Distribution
Medical - Distribution
AYTU vs PRGO vs TEVA vs MCK vs CAH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Medical - Distribution | Medical - Distribution |
| Market Cap | $16M | $1.61B | $41.93B | $92.15B | $43.59B |
| Revenue (TTM) | $63M | $4.18B | $17.35B | $403.43B | $250.55B |
| Net Income (TTM) | $-24M | $-1.82B | $1.56B | $4.76B | $1.56B |
| Gross Margin | 66.0% | 34.2% | 52.1% | 3.6% | 3.7% |
| Operating Margin | -13.9% | -4.1% | 13.2% | 1.5% | 0.9% |
| Forward P/E | — | 5.6x | 14.5x | 19.3x | 17.9x |
| Total Debt | $23M | $3.97B | $17.38B | $7.39B | $9.35B |
| Cash & Equiv. | $31M | $532M | $3.56B | $5.69B | $3.87B |
AYTU vs PRGO vs TEVA vs MCK vs CAH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Aytu BioPharma, Inc. (AYTU) | 100 | 0.8 | -99.2% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| Teva Pharmaceutical… (TEVA) | 100 | 287.4 | +187.4% |
| McKesson Corporation (MCK) | 100 | 474.1 | +374.1% |
| Cardinal Health, In… (CAH) | 100 | 338.7 | +238.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AYTU vs PRGO vs TEVA vs MCK vs CAH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, AYTU doesn't own a clear edge in any measured category.
PRGO has the current edge in this matchup, primarily because of its strength in sleep-well-at-night and defensive.
- Lower volatility, beta 1.18, current ratio 2.76x
- Beta 1.18, yield 9.8%, current ratio 2.76x
- Lower P/E (5.6x vs 17.9x)
- 9.8% yield, 10-year raise streak, vs CAH's 1.1%, (2 stocks pay no dividend)
TEVA is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 4.3%, EPS growth 182.8%, 3Y rev CAGR 5.0%
- 9.0% margin vs PRGO's -43.5%
- +104.6% vs PRGO's -51.2%
MCK ranks third and is worth considering specifically for long-term compounding.
- 348.1% 10Y total return vs CAH's 160.8%
- 16.2% revenue growth vs PRGO's -2.8%
- 5.7% ROA vs AYTU's -20.0%, ROIC 5.4% vs -33.5%
CAH is the clearest fit if your priority is income & stability.
- Dividend streak 20 yrs, beta 0.03, yield 1.1%
- Beta 0.03 vs AYTU's 1.27
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs PRGO's -2.8% | |
| Value | Lower P/E (5.6x vs 17.9x) | |
| Quality / Margins | 9.0% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.03 vs AYTU's 1.27 | |
| Dividends | 9.8% yield, 10-year raise streak, vs CAH's 1.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +104.6% vs PRGO's -51.2% | |
| Efficiency (ROA) | 5.7% ROA vs AYTU's -20.0%, ROIC 5.4% vs -33.5% |
AYTU vs PRGO vs TEVA vs MCK vs CAH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AYTU vs PRGO vs TEVA vs MCK vs CAH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
TEVA leads in 2 of 6 categories
PRGO leads 1 • MCK leads 1 • AYTU leads 0 • CAH leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
TEVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 6440.5x AYTU's $63M. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $63M | $4.2B | $17.3B | $403.4B | $250.5B |
| EBITDAEarnings before interest/tax | -$4M | $58M | $3.3B | $6.8B | $3.2B |
| Net IncomeAfter-tax profit | -$24M | -$1.8B | $1.6B | $4.8B | $1.6B |
| Free Cash FlowCash after capex | -$698,000 | $108M | $1.2B | $6.0B | $4.4B |
| Gross MarginGross profit ÷ Revenue | +66.0% | +34.2% | +52.1% | +3.6% | +3.7% |
| Operating MarginEBIT ÷ Revenue | -13.9% | -4.1% | +13.2% | +1.5% | +0.9% |
| Net MarginNet income ÷ Revenue | -39.0% | -43.5% | +9.0% | +1.2% | +0.6% |
| FCF MarginFCF ÷ Revenue | -1.1% | +2.6% | +6.8% | +1.5% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -6.5% | -7.2% | +2.3% | +6.0% | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.0% | -56.4% | +72.2% | +37.0% | -19.5% |
Valuation Metrics
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 28.7x trailing earnings, CAH trades at a 4% valuation discount to TEVA's 30.0x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than MCK's 18.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $16M | $1.6B | $41.9B | $92.1B | $43.6B |
| Enterprise ValueMkt cap + debt − cash | $7M | $5.1B | $55.8B | $93.8B | $49.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.14x | -1.14x | 30.01x | 29.25x | 28.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.56x | 14.55x | 19.28x | 17.94x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.75x | — |
| EV / EBITDAEnterprise value multiple | — | 7.42x | 17.65x | 18.74x | 16.01x |
| Price / SalesMarket cap ÷ Revenue | 0.23x | 0.38x | 2.43x | 0.26x | 0.20x |
| Price / BookPrice ÷ Book value/share | 0.82x | 0.55x | 5.34x | — | — |
| Price / FCFMarket cap ÷ FCF | — | 11.12x | 36.52x | 17.63x | 23.56x |
Profitability & Efficiency
MCK leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-172 for AYTU. AYTU carries lower financial leverage with a 1.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs AYTU's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -172.1% | -50.7% | +20.7% | +3.0% | — |
| ROA (TTM)Return on assets | -20.0% | -19.8% | +3.9% | +5.7% | +2.8% |
| ROICReturn on invested capital | -33.5% | +3.7% | +7.7% | +5.4% | +33.8% |
| ROCEReturn on capital employed | -13.3% | +4.3% | +8.0% | +30.5% | +19.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 8 | 6 | 6 |
| Debt / EquityFinancial leverage | 1.21x | 1.35x | 2.20x | — | — |
| Net DebtTotal debt minus cash | -$8M | $3.4B | $13.8B | $1.7B | $5.5B |
| Cash & Equiv.Liquid assets | $31M | $532M | $3.6B | $5.7B | $3.9B |
| Total DebtShort + long-term debt | $23M | $4.0B | $17.4B | $7.4B | $9.3B |
| Interest CoverageEBIT ÷ Interest expense | -7.96x | -7.20x | 2.51x | 33.79x | 6.38x |
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $215 for AYTU. Over the past 12 months, TEVA leads with a +104.6% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -10.8% | -13.5% | +16.3% | -8.5% | -9.5% |
| 1-Year ReturnPast 12 months | +104.1% | -51.2% | +104.6% | +4.6% | +22.0% |
| 3-Year ReturnCumulative with dividends | +40.3% | -58.1% | +297.5% | +106.4% | +127.3% |
| 5-Year ReturnCumulative with dividends | -97.8% | -60.1% | +246.2% | +286.9% | +235.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | -77.7% | -28.3% | +348.1% | +160.8% |
| CAGR (3Y)Annualised 3-year return | +12.0% | -25.2% | +58.4% | +27.3% | +31.5% |
Risk & Volatility
Evenly matched — TEVA and CAH each lead in 1 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than AYTU's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 1.18x | 1.13x | 0.04x | 0.03x |
| 52-Week HighHighest price in past year | $3.07 | $28.44 | $37.35 | $999.00 | $233.60 |
| 52-Week LowLowest price in past year | $1.20 | $9.23 | $14.99 | $637.00 | $137.75 |
| % of 52W HighCurrent price vs 52-week peak | +80.5% | +41.2% | +96.4% | +75.3% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 48.9 | 60.9 | 73.5 | 16.2 | 33.2 |
| Avg Volume (50D)Average daily shares traded | 42K | 3.4M | 6.6M | 757K | 1.7M |
Analyst Outlook
Evenly matched — PRGO and CAH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PRGO as "Hold", TEVA as "Buy", MCK as "Buy", CAH as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 8.3% for TEVA (target: $39). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $20.00 | $39.00 | $1006.50 | $249.67 |
| # AnalystsCovering analysts | — | 36 | 46 | 31 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% | — | +0.4% | +1.1% |
| Dividend StreakConsecutive years of raises | — | 10 | 1 | 17 | 20 |
| Dividend / ShareAnnual DPS | — | $1.15 | — | $2.69 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +3.4% | +1.8% |
TEVA leads in 2 of 6 categories (Income & Cash Flow, Total Returns). PRGO leads in 1 (Valuation Metrics). 2 tied.
AYTU vs PRGO vs TEVA vs MCK vs CAH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AYTU or PRGO or TEVA or MCK or CAH a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 9x forward), making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AYTU or PRGO or TEVA or MCK or CAH?
On trailing P/E, Cardinal Health, Inc.
(CAH) is the cheapest at 28. 7x versus Teva Pharmaceutical Industries Limited at 30. 0x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AYTU or PRGO or TEVA or MCK or CAH?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -97. 8% for Aytu BioPharma, Inc. (AYTU). Over 10 years, the gap is even starker: MCK returned +348. 1% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AYTU or PRGO or TEVA or MCK or CAH?
By beta (market sensitivity over 5 years), Cardinal Health, Inc.
(CAH) is the lower-risk stock at 0. 03β versus Aytu BioPharma, Inc. 's 1. 27β — meaning AYTU is approximately 3661% more volatile than CAH relative to the S&P 500. On balance sheet safety, Aytu BioPharma, Inc. (AYTU) carries a lower debt/equity ratio of 121% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — AYTU or PRGO or TEVA or MCK or CAH?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AYTU or PRGO or TEVA or MCK or CAH?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -11. 8% for AYTU. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AYTU or PRGO or TEVA or MCK or CAH more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — AYTU or PRGO or TEVA or MCK or CAH?
In this comparison, PRGO (9.
8% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. AYTU, TEVA do not pay a meaningful dividend and should not be held primarily for income.
09Is AYTU or PRGO or TEVA or MCK or CAH better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Both have compounded well over 10 years (CAH: +160. 8%, AYTU: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AYTU and PRGO and TEVA and MCK and CAH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AYTU is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; TEVA is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock. PRGO, CAH pay a dividend while AYTU, TEVA, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.